Angiotensin II receptor blockers in the treatment of heart failure

Congestive Heart Failure

Volumn 8, Issue 5, 2002, Pages 246-256

  Peterson, Ross C ^a   Dunlap, Mark E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; TELMISARTAN; VALSARTAN;

CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TOLERANCE; HEART FAILURE; HUMAN; HYPOTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0036751097     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2000.01156.x     Document Type: Review

References (49)

1. The CONSENSUS Trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
3. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
4. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
5. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial: the SAVE investigators. N Engl J Med. 1992;327:669-677.
6. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
7. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
8. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
9. Laragh JH, Sealey JE. Abnormal sodium metabolism and plasma renin activity (renal renin secretion) and the vasoconstriction volume hypothesis: implications for pathogenesis and treatment of hypertension and its vascular consequences. Clin Chem. 1991;37:1820-1827.
10. Doolittle RF. Angiotensinogen is related to the antitrypsin-antithrombin-ovalbumin family. Science. 1983;222:417-419.
11. Ng KK, Vane JR. Fate of angiotensin I in the circulation. Nature. 1968;218:144-150.
12. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2:294-306.
13. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987;59:59A-65A.
14. Muller DN, Fischli W, Clozel JP, et al. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res. 1998;82:13-20.
15. Dzau VJ, Hirsch AT. Emerging role of the tissue renin-angiotensin systems in congestive heart failure. Eur Heart J. 1990;11(B):65-71.
16. Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy. 1996;16:849-860.
17. Balcells E, Meng QC, Johnson WH, et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273:H1769-H1774.
18. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-392.
19. Siragy HM, Howell NL, Ragsdale NV, et al. Renal interstitial fluid angiotensin, modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension. 1995;25:1021-1024.
20. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 1984;2:581-587.
21. Sealey JE, Buhler FR, Laragh JH, et al. The physiology of renin secretion in essential hypertension. Estimation of renin secretion rate and renal plasma flow from peripheral and renal vein renin levels. Am J Med. 1973;55:391-401.
22. Bell L, Madri JA. Influence of the augiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7-12.
23. Daemen MJ, Lombardi DM, Bosman FT, et al. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
24. Timmermans, PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
25. Timmermans PB, Benfield P, Chiu AT, et al. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5:22IS-235S.
26. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis. 1993;22:745-754.
27. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension. 2000;35:1074-1077.
28. 2 receptor MRNA during development of rat kidney and adrenal gland. Am J Physiol. 1995;268:F922-F930.
29. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937-942.
30. 2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension. 1998;31:487-492.
31. Cao Z, Dean R, Wu L, et al. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension. 1999;34:408-414.
32. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) registry. Eur Heart J. 1999;20:1182-1190.
33. McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J. 1997;134:901-909.
34. Bart BA, Gattis WA, Diem SJ, et al. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 1997;79:1118-1120.
35. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
36. Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol. 1997;37:253-257.
37. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-107.
38. Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan cough study group. J. Hypertens. 1994;12:1387-1393.
39. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-617.
40. Riegger GA, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) investigators. Circulation. 1999;100:2224-2230.
41. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study investigators. J Am Coll Cardiol. 1997;30:983-991.
42. Havranek EP, Abrams F, Stevens E, et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med. 1998;158:2024-2028.
43. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet. 1997;349:747-752.
44. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet. 2000;355:1582-1587.
45. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999;99:990-992.
46. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation. 1999;100:1056-1064.
47. Cohn JN, Tognoni G, Glazer RD, et al. Rationale and design of the valsartan heart failure trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J. Card Fail. 1999;5:155-160.
48. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 1999;5:276-282.
49. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1999;1-29.